Surgical robots in 2026: Beyond da Vinci — Who is competing and what they can do

On April 21, 2026, Intuitive Surgical reported Q1 2026 revenue of $2.77 billion — a 23% year-on-year increase — with 11,395 da Vinci systems now installed globally, up 12% from a year earlier. These are not the numbers of a company under competitive duress. They are the numbers of a company entering a period of competitive challenge from a position of near-total market dominance — with a moat built from 25 years of installed base, surgeon training, proprietary instrument ecosystems, and service contracts that generate recurring revenue irrespective of system sales. The surgical robotics market stood at $13.69 billion in 2025 and is projected to reach $27.14 billion by 2030, per MarketsandMarkets — one of the fastest-growing segments in medical devices, which is precisely why the competitive field has become crowded.

The marketing narrative from the challenger camp — Medtronic, CMR Surgical, Johnson & Johnson, Stryker, and a cohort of well-funded new entrants — emphasises modular design, lower capital cost, and platform flexibility as the wedge against Intuitive. The evidence-based tension is sharper: modularity and flexibility are real advantages in operating room logistics, but they do not answer the question hospitals actually wrestle with — whether the clinical outcomes justify the transition cost, the surgeon retraining burden, and the disruption to existing contracts. A 2025 narrative review in PMC examining robotic versus laparoscopic surgery across specialties found that robotic-assisted surgery shows ‘positive results’ in precision and conversion rates in some procedures, but that ‘results regarding operative duration, postoperative complications, and cost-effectiveness remain heterogeneous.’ That heterogeneity is the honest backdrop against which every new entrant must make its case.

This article covers the six platforms with the most material 2025–2026 regulatory or commercial developments: Intuitive Surgical’s da Vinci 5, Medtronic’s Hugo, CMR Surgical’s Versius Plus, Johnson & Johnson’s Ottava, Stryker’s Mako 4 and Mako RPS, and Virtuoso Surgical’s endoscopic robot. It is a field report on the state of competition at the moment it actually begins.

Intuitive Surgical’s da Vinci 5: 11,395 systems, $10B+ in revenue, and a force-sensing moat

By December 31, 2025, Intuitive had 11,106 da Vinci systems installed globally, growing to 11,395 by March 31, 2026. Full-year 2025 revenue exceeded $10 billion — driven overwhelmingly by instruments and accessories (~56% of total revenue), not system sales. A hospital that installs a da Vinci system becomes a recurring consumables customer, with instrument costs running USD 700–3,500 per case. Intuitive’s 2024 data shows approximately $3,300 per case in instruments and services revenue — an ‘absolute floor’ per the American College of Surgeons February 2026 cost analysis.

The da Vinci 5, now comprising the majority of new system placements (303 of 486 in Q4 2025), adds force-sensing technology — giving surgeons simulated haptic feedback for the first time in da Vinci’s history — and integrated AI-driven performance analytics via the Intuitive Hub. Intuitive’s 2026 guidance forecasts worldwide procedure growth of 13–15% — below 2025’s 18% — citing Medicaid funding impacts, European capital constraints, and China competition as headwinds. Gary Guthart, Intuitive CEO, noted in the Q4 2025 earnings call that the company is ‘watching the competitive environment carefully while investing in our innovation pipeline.’ The growth rate moderation is the first signal that competitive pressure is registering in Intuitive’s own projections.

The honest constraint: da Vinci’s cost structure is the highest in the market. System purchase prices run USD 1–2.5 million, with annual service contracts of USD 100,000–200,000. The proprietary instrument ecosystem means hospitals cannot mix da Vinci with third-party consumables — a lock-in challengers are explicitly targeting in their procurement conversations.

Medtronic Hugo: the first large-medtech US clearance since Intuitive — and what it actually covers

On December 3, 2025, Medtronic received FDA clearance for the Hugo RAS system for urologic surgical procedures — specifically prostatectomy, nephrectomy, and cystectomy, accounting for approximately 230,000 US cases annually. The clearance makes Medtronic the first large medtech company to enter the US soft-tissue robotic surgery market since Intuitive’s original clearance, per MedTech Dive’s December 2025 reporting.

Hugo’s design differentiation is structural: modular robotic arms on separate carts, an open surgeon console (not an enclosed cockpit), and integration with Medtronic’s Touch Surgery ecosystem for surgical performance analytics. The modular cart design means arms can be repositioned between cases and shared across operating rooms — addressing a real hospital operational constraint. Outside the US, Hugo has been used in tens of thousands of procedures across more than 30 countries.

The honest constraint: Hugo’s US commercial launch is a ‘purposeful’ limited rollout — targeting leading hospital systems first to build clinical evidence and service infrastructure. Hugo has no published US randomised controlled trial data against da Vinci as of June 2026. Any hospital evaluating Hugo in 2026 is accepting early-adopter risk on US service infrastructure, surgeon training pipeline, and long-term consumables pricing.

CMR Surgical Versius Plus and J&J Ottava: two different stages of the same race

Cambridge, UK-based CMR Surgical secured 510(k) FDA clearance for Versius Plus on December 17, 2025 — for cholecystectomy (gallbladder removal), the most common elective abdominal surgery in the US. Outside the US, CMR’s platform has completed more than 40,000 procedures. The company raised USD 200 million in April 2025, backed by SoftBank, Tencent, and Ally Bridge Group, specifically for US commercialisation.

Versius Plus mirrors Hugo’s modularity argument: portable cart-mounted arms, no dedicated OR required, flexible port placement, an open console, and adoption of NVIDIA IGX THOR for AI-powered real-time surgical insights. The clinical evidence base outside the US spans multiple specialties, but the US regulatory indication is limited to cholecystectomy as of June 2026 — each new indication requires an additional 510(k) submission or De Novo application.

Johnson & Johnson is at a different regulatory stage. On January 7, 2026, J&J submitted Ottava to the FDA for De Novo classification, targeting multiple upper-abdominal general surgery procedures — gastric bypass, gastric sleeve, small bowel resection, and hiatal hernia repair. The first clinical cases were performed in April 2025 at Memorial Hermann-Texas Medical Center by Dr. Erik Wilson, Chief of Minimally Invasive and Elective General Surgery at UT Health Houston. The critical caveat: De Novo review timelines typically run 12–24 months for complex devices.

Stryker Mako 4 and Mako RPS: why orthopaedic robotics is already post-competition

Stryker’s Mako platform is already close to the standard of care for joint replacement in the US. More than two-thirds of Stryker’s US knee procedures and one-third of US hip procedures are performed using a Mako robot, per MedTech Dive’s January 2026 reporting. Over 1.5 million Mako procedures have been performed globally across 45 countries, with more than 3,000 Mako systems installed worldwide.

Mako 4, launched at the AAOS 2025 annual meeting in March 2025, adds coverage across hip, knee, partial knee, and spine on a single system. The most strategically significant new development is Mako RPS (Robotic Power System), a handheld miniaturised variant cleared by FDA in August 2025 and entering limited market release in early 2026, targeting ambulatory surgery centres (ASCs). CEO Kevin Lobo described it as ‘an extra accelerator’ for Stryker’s knee business.

The honest constraint: Mako is optimised for Stryker’s Triathlon and Accolade implant systems. Full clinical benefit is tied to Stryker implants — displacing Mako at an account level requires not just a competitive robotic platform but a parallel implant transition. Johnson & Johnson’s Velys, Zimmer Biomet’s ROSA, and Smith & Nephew’s CORI all compete in orthopaedic robotics, but none has dented Mako’s installed base leadership as of June 2026.

The cost question every hospital CFO is asking — and what the evidence actually says

The American College of Surgeons’ February 2026 cost analysis calculated an ‘absolute floor’ of approximately $3,300 per robotic case — compared to disposable costs of less than $1,000 for a laparoscopic cholecystectomy. Capital cost differential is separate: da Vinci 5 at USD 1–2.5 million versus a laparoscopic tower at USD 20,000–80,000.

Where robotic surgery has the strongest cost-effectiveness evidence: prostatectomy (reduced blood loss, shorter hospital stay, lower complication rates); rectal cancer surgery (lower conversion rates to open surgery); and complex pelvic procedures where robotic instrument articulation provides access advantages laparoscopic tools cannot replicate.

Where the evidence is weakest: cholecystectomy, appendectomy, and hernia repair — where robotic cases run $18,300 average hospitalisation cost versus $16,000 for laparoscopic, with no demonstrated complication rate advantage in most studies. The PMC 2025 narrative review concluded robotic surgery is associated with ‘longer procedure time and shorter hospital stay’ in colorectal cases, but that cost-effectiveness evidence ‘remains heterogeneous.’ This matters acutely for challengers: Hugo, Versius Plus, and Ottava all target general surgery — precisely where the economic case for robotics is least established.

The platforms that don’t fit the existing categories — and three signals the market is expanding

Virtuoso Surgical’s September 2025 FDA Breakthrough Device Designation is the most structurally distinct development in the 2025–2026 period. Unlike every other platform in this article, Virtuoso’s system uses needle-sized robotic arms deployed through rigid endoscopes — not external robotic arms entering through trocar ports. CEO and urologic surgeon Dr. Duke Herrell described it as ‘unlike any surgical robot available today’, targeting en bloc bladder lesion removal for bladder cancer staging. Commercialisation is pre-clinical-trial stage as of June 2026.

Three signals that the surgical robotics category boundary is shifting beyond the soft-tissue vs orthopaedics binary:

• Cardiac surgery expansion. The MedTech Dive 2026 surgical robotics trend analysis identifies cardiac surgery as Intuitive’s next US expansion frontier for da Vinci 5, with limited rollout beginning in 2026 at selected hospitals building cardiac robotic programmes. No challenger has an established position in this procedure category.
• AI regulatory formalisation. The FDA’s published framework for AI/ML-enabled medical devices, updated through 2025, and joint EMA-FDA guiding principles issued in January 2026 are formalising the regulatory pathway for AI-integrated surgical platforms. Platforms with larger procedure datasets — Intuitive most of all — benefit disproportionately from this trend in the near term.
• Endoscopic miniaturisation. Virtuoso’s approach — robotic manipulation inside existing endoscopic channels rather than through separate trocar ports — points toward a third generation of surgical robots that does not require the operating room infrastructure either da Vinci or its modular challengers depend on. This is the design direction most likely to reach the outpatient and ambulatory surgery setting first.

The IntuitionLabs 2026 surgical AI landscape analysis documents more than 40 AI-assisted surgical companies now operating across imaging, guidance, and autonomous task execution — signalling that the competitive surface in surgical robotics is expanding beyond platform hardware into the software and AI integration layer, where incumbency advantages are less durable.

Bottom Line

The December 2025 regulatory cluster — Hugo clearance, Versius Plus clearance, Ottava submission — is a genuine inflection point, not a marketing narrative. Intuitive’s 11,395-system installed base and $2.77 billion quarterly revenue are not threatened in the near term: procedure momentum, surgeon training, service infrastructure, and da Vinci 5’s force-sensing and AI integration all reinforce the moat. What has changed is the structure of choice available to hospital procurement teams for the first time in a generation. Hugo offers modular flexibility with a major medtech service network behind it. Versius Plus offers the lowest-footprint deployment model for facilities that cannot justify a dedicated robotic OR. Ottava, if cleared, brings J&J’s Ethicon instrument expertise to a unified-architecture platform. None of these replaces da Vinci in 2026. Each has a specific use case where it outperforms the status quo.

What you should do differently because of this article: if you are evaluating a soft-tissue robotic programme for the first time, Hugo and Versius Plus are now viable alternatives for a constrained set of procedures — but demand published US clinical outcomes data, not international equivalence claims, before committing capital. If you are evaluating an orthopaedic programme, Mako 4 is established standard of care; the decision is whether to adopt robotics at all. If you are an Intuitive customer considering competitors, the transition cost — surgeon retraining, service contract renegotiation, consumables migration — is real and largely unquantified in challenger marketing. And watch the FDA’s De Novo timeline for Ottava: J&J’s commercial scale, Ethicon instrument integration, and the scope of the Ottava indication could make its eventual clearance the most consequential competitive development in this landscape.

Key Sources

• Intuitive Surgical Q1 2026 Earnings — $2.77B revenue, 11,395 systems (Apr 2026)
• Intuitive Surgical Q4 2025 Earnings — Full-year results, 870 da Vinci 5 placements (Jan 2026)
• Medtronic — FDA Clearance of Hugo RAS System for Urologic Procedures (Dec 3, 2025)
• MedTech Dive — Medtronic’s Hugo surgical robot earns FDA clearance (Dec 2025)
• CMR Surgical — Versius Plus 510(k) FDA Clearance (Dec 17, 2025)
• The Robot Report — CMR Surgical receives FDA clearance for Versius Plus (Dec 2025)
• Johnson & Johnson — Ottava Robotic Surgical System Submitted to FDA (Jan 7, 2026)
• J&J MedTech — First Cases Completed with OTTAVA at Memorial Hermann-Texas (Apr 2025)
• Stryker — Mako 4 Next-Generation Launch at AAOS 2025 (Mar 2025)
• MedTech Dive — Stryker Mako RPS Limited Market Release (Feb 2026)
• MedTech Dive — 5 Robotic Surgery Trends to Watch in 2026 (Jan 2026)
• American College of Surgeons — Cost of Robotic Surgery: A Complex Equation (Feb 2026)
• PMC — Robotic vs. Laparoscopic Surgery: Comparative Assessment of Outcomes and Cost (2025)
• Virtuoso Surgical — FDA Breakthrough Device Designation for Bladder Lesion Robot (Sep 2025)
• FDA — AI/ML-Enabled Medical Devices: Published Framework and Action Plan
• IntuitionLabs — AI-Assisted Surgery Landscape: 40+ Companies, FDA Guidance (2026)
• MarketsandMarkets — Surgical Robots Market: $13.69B (2025) to $27.14B by 2030